Giovanni Caforio, M.D. has been chief executive officer of Bristol Myers Squibb since May 2015 and has been serving on the company’s Board of Directors since June 2014. In May 2017, he assumed the role of chairman of the board.
As CEO, Giovanni has led the company’s focus on researching and developing transformational medicines, which includes a leading portfolio of immunotherapies that are fundamentally changing the way cancer is treated. Under his leadership, BMS is evolving its operating model, in order to increase speed and competitiveness.
With a background as a physician, Giovanni has helped strengthen the company’s patient-focused culture -- one driven by innovation, speed, accountability and passion. As a leader, he is focused on the business value of a company culture that promotes and rewards diversity and inclusion.
Prior to becoming CEO, Giovanni served as chief operating officer with responsibility for leading a fully integrated worldwide commercial organization and the companywide functions of Enterprise Services and Global Manufacturing & Supply. This was preceded by his work as the company’s chief commercial officer.
Giovanni joined Bristol Myers Squibb in 2000 as vice president and general manager, Italy, in the Worldwide Medicines Group. He assumed added responsibility for Greece and Israel in 2001, and for South East Europe in 2003. In 2004, he was appointed senior vice president, European Marketing and Brand Commercialization. In 2007, he relocated to the US to assume the role of senior vice president, U.S. Oncology. In 2010, he was named senior vice president, Global Commercialization, Oncology and Immunology, before becoming president of the company’s U.S. organization in 2011. Prior to joining Bristol Myers Squibb, Giovanni spent 12 years with Abbott Laboratories in a number of leadership positions.
Born and educated in Italy, Giovanni received his M.D. from the University of Rome.
What is Giovanni Caforio's net worth?
The estimated net worth of Giovanni Caforio is at least $13.90 million as of February 6th, 2023. Dr. Caforio owns 236,104 shares of Bristol-Myers Squibb stock worth more than $13,899,442 as of November 23rd. This net worth evaluation does not reflect any other investments that Dr. Caforio may own. Learn More about Giovanni Caforio's net worth.
How do I contact Giovanni Caforio?
Has Giovanni Caforio been buying or selling shares of Bristol-Myers Squibb?
Giovanni Caforio has not been actively trading shares of Bristol-Myers Squibb during the past quarter. Most recently, Giovanni Caforio sold 240,000 shares of the business's stock in a transaction on Monday, February 6th. The shares were sold at an average price of $74.65, for a transaction totalling $17,916,000.00. Following the completion of the sale, the chief executive officer now directly owns 236,104 shares of the company's stock, valued at $17,625,163.60. Learn More on Giovanni Caforio's trading history.
Who are Bristol-Myers Squibb's active insiders?
Bristol-Myers Squibb's insider roster includes Mark Alles (CEO), Christopher Boerner (EVP), Giovanni Caforio (CEO), Adam Dubow (SVP), Joseph Eid (SVP), John Elicker (EVP), David Elkins (CFO), Samit Hirawat (EVP, Chief Medical Officer and Head of Development), Sandra Leung (EVP), Dinesh Paliwal (Director), Robert Plenge (EVP), Ann Powell (EVP), Theodore Samuels, II (Director), Karen Santiago (SVP), Louis Schmukler (EVP), Rupert Vessey (EVP), and Paul von Autenried (EVP). Learn More on Bristol-Myers Squibb's active insiders.
Are insiders buying or selling shares of Bristol-Myers Squibb?
During the last year, Bristol-Myers Squibb insiders bought shares 3 times. They purchased a total of 6,901 shares worth more than $349,655.16. During the last year, insiders at the biopharmaceutical company sold shares 1 times. They sold a total of 700 shares worth more than $38,934.00. The most recent insider tranaction occured on November, 4th when SVP Phil M Holzer sold 700 shares worth more than $38,934.00. Insiders at Bristol-Myers Squibb own 0.1% of the company.
Learn More about insider trades at Bristol-Myers Squibb. Information on this page was last updated on 11/4/2024.
